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This article has been corrected since Online Publication and a corrigendum has also been published
I Karl1, M Jossberger-Werner1, N Schmidt1, S Horn2, M Goebeler1, M Leverkus2, H Wajant3 and T Giner*,1
The relevance of the adaptor protein TNF receptor-associated factor 2 (TRAF2) for signal transduction of the death receptor
tumour necrosis factor receptor1 (TNFR1) is well-established. The role of TRAF2 for signalling by CD95 and the TNF-related
apoptosis inducing ligand (TRAIL) DRs, however, is only poorly understood. Here, we observed that knockdown (KD) of
TRAF2 sensitised keratinocytes for TRAIL- and CD95L-induced apoptosis. Interestingly, while cell death was fully blocked by
the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk) in control cells, TRAF2-depleted
keratinocytes were only partly rescued from TRAIL- and CD95L-induced cell death. In line with the idea that the only partially
protective effect of zVAD-fmk on TRAIL- and CD95L-treated TRAF2-depleted keratinocytes is due to the induction of necroptosis,
combined treatment with zVAD-fmk and the receptor interacting protein 1 (RIP1) inhibitor necrostatin-1 fully rescued these cells. To
better understand the impact of TRAF2 levels on RIP1- and RIP3-dependent necroptosis and RIP3-independent apoptosis, we
performed experiments in HeLa cells that lack endogenous RIP3 and HeLa cells stably transfected with RIP3. HeLa cells, in which
necroptosis has no role, were markedly sensitised to TRAIL-induced caspase-dependent apoptosis by TRAF2 KD. In RIP3-
expressing HeLa transfectants, however, KD of TRAF2 also strongly sensitised for TRAIL-induced necroptosis. Noteworthy,
priming of keratinocytes with soluble TWEAK, which depletes the cytosolic pool of TRAF2-containing protein complexes, resulted
in strong sensitisation for TRAIL-induced necroptosis but had only a very limited effect on TRAIL-induced apoptosis. The
necroptotic TRAIL response was not dependent on endogenously produced TNF and TNFR signalling, since blocking TNF by
TNFR2-Fc or anti-TNFα had no effect on necroptosis induction. Taken together, we identified TRAF2 not only as a negative
regulator of DR-induced apoptosis but in particular also as an antagonist of TRAIL- and CD95L-induced necroptosis.
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Death receptors (DRs) constitute a subgroup of the tumour
necrosis factor receptor (TNFR) superfamily and are charac-
terised by their cytoplasmic ‘death domain’. Stimulation of the
prototypic DRs TNF-related apoptosis inducing ligand (TRAIL)
receptor-1 (TRAILR1), TRAILR2 orCD95 by their ligands TRAIL
and CD95L leads to recruitment of the adaptor proteins Fas-
associated death domain (FADD) and of caspase-8. In the so
formed death inducing signalling complex (DISC), caspase-8
undergoes proximity-induced maturation to the enzymatically
fully active heterotetrameric caspase-8 molecule which is
released from the DISC.1,2 TNFR1 is also a DR, but acts
in vivo primarily as a driver of inflammatory processes and less
as an inducer of cell death. TNFR1 signals apoptosis not via a
receptor-associatedDISC but via a secondarily formed cytosolic
caspase-8 activating complex.3,4
Keratinocytes express TRAILR1 and TRAILR2 as well as
CD95 and can undergo apoptosis upon TRAIL or CD95L
stimulation under defined circumstances.5–7 The well-
balanced activity of DR-associated apoptotic and non-
apoptotic signalling pathways in the skin is thus crucial for
skin physiology. Pathological disturbance of the balance
between these pathways may lead to skin cancer or
inflammatory skin conditions such as psoriasis, alopecia
areata or toxic epidermal necrolysis.8,9
Noteworthy, DRs may also trigger a caspase-independent
mode of cell death.10,11 This caspase-independent form of
DR-induced programmed cell death has been termed
necroptosis and is characterised by swelling of the organelles,
increased cell volume and disruption of the plasmamembrane
subsequently leading to inflammation.12,13 Mechanisms that
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inhibit necroptosis are critical for maintenance of tissue
homeostasis. So far, induction of necroptosis has mainly been
investigated after stimulation of TNFR1 or CD95, but has also
been suggested for TRAIL.14–16
At the molecular level one crucial determinant of the quality
of the DR response is the serine threonine kinase RIP1. Like
FADD and caspase-8, RIP1 is recruited to liganded DRs but it
is also part of cytosolic caspase-8 activating complexes
formed in response to TNF, genotoxic stress or depletion of
the E3 ligases cellular inhibitor of apoptosis protein 1 and 2
(cIAP1 and cIAP2).4,17–20 Dependent on the availability of the
anti-apoptotic caspase-8 homologue FLICE-inhibitory protein
long (FLIP-L), cIAP1/2 and the RIP1-related kinase RIP3, the
cytoplasmic RIP1/caspase-8 containing complexes can lead
to RIP3-dependent necroptosis12 or caspase-8-mediated
apoptosis,4 but presumably also to RIP1-mediated activation
of the anti-apoptotic classical nuclear factor κB (NFκB)
pathway.21,22 The kinase activity of RIP1 is required for the
induction of necroptosis but seems to be dispensable for its
NFκB and caspase-8 stimulating activities.23,24
TRAF2 has been initially described as a cytosolic adaptor
protein that not only interacts with the cytoplasmic part of
various non-DRs of the TNFR family but also mediates
recruitment of the E3 ligases cIAP1 and cIAP2.25 It turned
out that the TRAF2/cIAP complex is also indirectly recruited to
some DRs, particularly to TNFR1.26 TRAF2 and the cIAPs
typically contribute to a varying extent to stimulation of
signalling pathways, resulting in the activation of NFκB
transcription factors and MAP kinases. While the K63 E3
ligase activity of cIAP1 and cIAP2 is of pivotal relevance there
is also evidence that TRAF2 can act itself as a K48E3 ligase of
caspase-8 that triggers proteasomal degradation of the
maturated enzyme.27 However, the E3 ligase activity of
TRAF2 is controversially discussed.28–30
In the current study, we investigated the relevance of TRAF2
for the cell death response to TRAIL and CD95L stimulation.
It turned out that TRAF2 is involved in protection against
TRAIL- and CD95L-induced apoptosis but above all against
TRAIL- and CD95L-induced necroptosis.
Results
TRAF2 knockdown sensitises HaCaT keratinocytes for
TRAIL-induced cell death. To investigate the relevance of
TRAF2 for TRAIL DR-induced cell death in keratinocytes,
TRAF2 was depleted in HaCaT cells by RNA interference.
Cells were then stimulated with Killer-TRAIL, a highly active,
commercially available form of TRAIL, and evaluated for
viability and molecular markers of cell death. HaCaT
keratinocytes with reduced TRAF2 levels were markedly
sensitised for TRAIL-induced cell death. Crystal violet
staining revealed an ~ 16-fold lower lethal dose 50% for
Killer-TRAIL-induced cell death in TRAF2 small interfering
RNA (siRNA)-transfected cells as compared with cells
transfected with an irrelevant control siRNA (Figure 1a). In
line with this finding, TRAIL-induced externalisation of
phosphatidylserine was increased in TRAF2 knockdown
(KD) cells (Figure 1b) and came along with increased
detachment from the plastic surface (Figure 1c). TRAIL-
induced cell death was furthermore accompanied by activa-
tion and cleavage of caspases and this was also moderately
enhanced after TRAF2 KD. Cleavage of caspase-8 and
caspase-3 as well as of the caspase-3 substrate PARP and of
RIP1 was equal or even more intense in the TRAF2 KD
keratinocytes after 1–3 h (Figure 1d).
TRAIL induces necroptosis in HaCaT keratinocytes upon
TRAF2 KD and caspase inhibition. TRAIL-induced cell
death correlated with activation of caspases. To explore
whether caspase activation is required for TRAIL-induced cell
death in TRAF2 KD cells or whether necroptosis contributed
to overall cell death, we next analysed the effects of the
pan-caspase inhibitor zVAD-fmk and of the RIP1-inhibitor
necrostatin-1 (Nec) on TRAIL-induced cell death. In cells
transfected with control siRNA, TRAIL-induced cell death was
largely blocked by zVAD-fmk (Figures 2a and b). Surprisingly,
TRAF2 KD not only sensitised for TRAIL-induced cell death,
but also changed the character of the TRAIL cell death
response. In the presence of zVAD-fmk, and in marked
contrast to control cells, TRAF2 siRNA-transfected cells were
only partly rescued by zVAD-fmk (Figures 2a and b). This
could also be reproduced with independent functional
siRNA’s for TRAF2 (Supplementary Figure S8). To confirm
that caspase inhibition by zVAD-fmk was effective, we
performed Western blot analysis of TRAIL-exposed TRAF2-
depleted and control siRNA-transfected HaCaT cells. Treat-
ment with zVAD-fmk indeed prevented TRAIL-induced
processing of caspases-3 and -8 in control siRNA- and
TRAF2 siRNA-transfected cells (Figure 2c). Preincubation
with the RIP1 inhibitor necrostatin-1 alone showed no
protective effect on TRAIL-induced cell viability irrespective
of TRAF2 KD (Figure 2d). However, in contrast to zVAD-fmk,
a mixture of zVAD-fmk and necrostatin-1 completely rescued
TRAIL-stimulated TRAF2-depleted keratinocytes (Figure 2d).
These data indicate that TRAF2 KD sensitises keratinocytes
for RIP1-mediated necroptosis under conditions of impaired
caspase-8 activation.
CD95 stimulation leads to increased apoptosis and
necroptosis in TRAF2 KD HaCaT keratinocytes. CD95
and the TRAIL DRs signal by quite similar mechanisms.
Therefore, we next analysed CD95-mediated cell death in
TRAF2 KD keratinocytes. CD95L-treated HaCaT cells with
TRAF2 KD exhibited a higher sensitivity to CD95L-induced
cell death as compared with controls (Figures 3a and b).
Caspase-8 and caspase-3 processing as well as cleavage of
RIP1 was enhanced in TRAF2 KD HaCaT cells and was fully
inhibited by preincubation with zVAD-fmk (Figure 3c). CD95-
mediated cell death, however, was fully blocked by caspase
inhibition only in the control siRNA-transfected, but not in the
TRAF2 siRNA-transfected HaCaT cells (Figure 3d). As with
TRAIL, the caspase-independent form of cell death occurring
in CD95-stimulated zVAD-fmk-treated TRAF2 KD cells was
rescued in the presence of necrostatin-1 (Figure 3d).
TRAF2 KD in primary keratinocytes unleashes DR-
induced necroptosis when caspase activity is
impaired. HaCaT cells are a spontaneously transformed
keratinocyte cell line that shares many but not all properties
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of primary keratinocytes.31 We therefore analysed the effects
of TRAF2 KD on TRAIL- and CD95L-induced cell death in
primary keratinocytes. In contrast to HaCaT cells, primary
keratinocytes express high levels of FLIP-L and are therefore
largely resistant towards TRAIL- and CD95L-induced cell
death.6 Interestingly, KD of TRAF2 enabled CD95L and
TRAIL to induce cell death in primary keratinocytes (Figures
4a and d). Western Blot analysis furthermore revealed
increased caspase-3 processing in TRAF2 KD keratinocytes
after CD95L stimulation, whereas caspase-8 cleavage to
p43/41 remained largely unchanged (Figure 4b). Intriguingly,
preincubation with zVAD-fmk inhibited DR-induced proces-
sing of caspase-8 and caspase-3 to p18 and p20/17/15 but
enhanced cell death induction in the TRAF2 KD cells (Figures
4b and c). Co-incubation with necrostatin-1 and zVAD-fmk
restored TRAIL resistance in control-transfected as well
as in TRAF2 KD keratinocytes (Figure 4d). This argues for
an anti-necroptotic activity of TRAF2 in the context of DR
signalling not only in HaCaT cells but also in primary
keratinocytes.
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Figure 1 TRAF2 knockdown sensitises HaCaT keratinocytes for TRAIL-induced cell death. HaCaT keratinocytes were transfected with control siRNA and TRAF2 siRNA.
Experiments were performed 24–96 h after transfection. Knockdown efficiency was controlled by Western blotting (insert in a). (a) HaCaT cells treated with control siRNA or
TRAF2 siRNA were stimulated in triplicates with the indicated concentrations of Killer-TRAIL for 18 h and viability was measured by crystal violet staining. One representative
experiment of four independent experiments is shown. Heat-shocked (55 °C for 30 min) cells were analysed as a positive control for the detection of necrotic cells. (b) HaCaT cells
transfected with control siRNA and TRAF2 siRNAwere stimulated for 6 h with Killer-TRAIL (64 ng/ml), stained with Annexin-PE and 7-AAD and finally analysed by flow cytometry.
(c) HaCaT keratinocytes with or without TRAF2 knockdown were stimulated with 4 ng/ml Killer-TRAIL for 18 h and cellular morphology was documented by light microscopy.
(d) Cells transfected with control and TRAF2-targeting siRNA were stimulated with 64 ng/ml Killer-TRAIL. After 1 and 3 h total cell lysates were prepared and subjected to
Western Blot analysis to detect the indicated proteins
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RIP3 expression confers competence for TRAIL-induced
necroptosis. The data presented so far indicate that TRAF2
antagonises caspase activation and particularly necroptosis
induction by TRAIL and CD95L in keratinocytes. To study
whether this also applies to another epithelial cell type,
we investigated the human cervical cancer cell line HeLa.
As HeLa cells lack expression of RIP3,32 which is a
crucial component of the DR-induced necroptotic pathway,
we compared control-transfected HeLa cells with HeLa
cells stably overexpressing RIP3 (Figure 5a, right
panel). In line with the data obtained from keratinocytes,
HeLa control transfectants and the RIP3-expressing
transfectants were sensitised for TRAIL-induced cell death
after TRAF2 KD (Figure 5a). Not unexpected in view of the
lack of RIP3 expression in the HeLa control transfectants,
these cells were completely rescued from TRAIL-induced
cell death by zVAD-fmk even after TRAF2 KD (Figure 5b,
left panel). However, in the RIP3 expressing transfectants,
treatment with zVAD-fmk resulted in sensitisation for
TRAIL-induced cell death. This effect was even stronger
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Figure 2 TRAIL induces necroptosis in HaCaT keratinocytes upon TRAF2 knockdown and caspase inhibition. HaCaT keratinocytes were transfected with control siRNA
or TRAF2 siRNA. Experiments were performed 24–96 h after transfection. (a) Control siRNA and TRAF2 siRNA-transfected HaCaT cells were pretreated with the pan-
caspase inhibitor zVAD-fmk (40 μM, 30 min) and then stimulated with Killer-TRAIL (64 ng/ml) for 8 h. Finally, cells were stained with Annexin-PE and 7-AAD and subjected to
flow cytometric analysis. A diagram depicting the mean values of all three experiments is shown in b. Statistically significant differences (P≤ 0,05; student’s t-test) were
marked by *. (c) siRNA transfected HaCaT keratinocytes were treated with Killer-TRAIL (100 ng/ml) for 1 h or 3 h with or without zVAD-fmk. Western blot analysis was
performed to detect the indicated proteins. (d) Control siRNA or TRAF2 siRNA-transfected HaCaT cells were pretreated with the indicated mixtures of the pan-caspase
inhibitor zVAD-fmk (40 μM) and the RIP1 inhibitor necrostatin-1 (90 μM) for 60 min and then cells were challenged with Killer-TRAIL (16 ng/ml). Cell viability was quantified by
crystal violet staining after 20 h
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Figure 3 Induction of apoptosis and necroptosis by Fc-CD95L is enhanced in TRAF2 knockdown HaCaT keratinocytes. Experiments were performed essentially as
described in the legends of Figures 1 and 2 but cells were stimulated with Fc-CD95L instead of TRAIL. (a) Control siRNA- and TRAF2 siRNA-transfected HaCaT cells were
stimulated overnight with Fc-CD95L and finally analysed for their viability using crystal violet staining. (b) Cells were stimulated with Fc-CD95L (64 ng/ml) for 6 h and then stained
with Annexin-PE and with 7-AAD. The numbers in each quadrant indicate the percentage of all cells present in the corresponding quadrant. (c) TRAF2 siRNA and control siRNA-
transfected HaCaT were pretreated with DMSO (solvent control) or zVAD-fmk (40 μM) for 30 min and were then stimulated with Fc-CD95L (250 ng/ml) for 1 or 3 h. Total cell
lysates were analysed by Western blotting for the presence of the indicated proteins. One out of two representative experiments is shown. (d) HaCaT cells were treated with the
indicated siRNAs. The next day, cells were preincubated with zVAD-fmk (40 μM) alone or in combination with necrostatin-1 (90 μM) for 60 min and then stimulated with Fc-CD95L
(16 ng/ml) overnight. Viability was measured by crystal violet staining
TRAF2 inhibits necroptosis
I Karl et al
5
Cell Death and Disease
after TRAF2 KD (Figure 5b, right panel). Co-treatment of
RIP3-expressing HeLa cells with a mixture of zVAD-fmk and
necrostatin-1 was strongly protective irrespective of TRAF2
KD, proving the relevance of the necroptotic mode of TRAIL-
induced cell death in these cells (Figure 5b). TRAIL-induced
caspase processing was generally more intense in the RIP3-
transfected cells and TRAF2 KD enhanced TRAIL-induced
caspase activation irrespective of the RIP3 expression status
(Figure 5c and Supplementary Figure S1). Altogether these
data suggest (i) that RIP3 is crucial for TRAIL-induced
necroptosis, (ii) that RIP3 may also enhance TRAIL-induced
caspase activation and (iii) that TRAF2 antagonises both
apoptosis and necroptosis induction by TRAIL.
Depletion of cytoplasmic TRAF2/cIAP complexes by Fn14
activation and a cIAP antagonist sensitise for TRAIL-
induced necroptosis. Artificial downregulation of TRAF2
expression by siRNA might have a physiological equivalent.
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Figure 4 TRAF2 knockdown in primary keratinocytes unleashes death receptor-induced necroptosis when caspase activity is impaired. (a) Primary human keratinocytes
were transiently transfected with TRAF2 siRNA or control siRNA. 24 h after transfection cells were stimulated with Fc-CD95L (64 ng/ml) or TRAIL (64 ng/ml). After 6 h, cells were
stained with Annexin-PE and 7-AAD and evaluated by flow cytometric analysis. (b) Two days after siRNA transfection, primary keratinocytes were preincubated for 1 h with zVAD-
fmk (40 μM) or necrostatin-1 (90 μM), either alone or in combination. Cells were then stimulated with Fc-CD95L (64 ng/ml) for additional 3 h and processing of caspase-8 and
caspase-3 was analysed by Western blotting. Tubulin served as a load control. (c) Primary keratinocytes obtained from five different donors (PK1-PK5) were transfected either
with TRAF2 siRNA or control siRNA (transfection efficiency is shown in the upper panel). Transfected primary keratinocytes were preincubated with zVAD-fmk (40 μM) and then
stimulated with Killer-TRAIL (64 ng/ml) for 6 h. Cells were then stained with Annexin-PE and 7-AAD and analysed by flow cytometry. The diagrams depicted in the lower panel
show the percentage of Annexin-PE and/or 7-AAD-positive keratinocytes from all five donors at the indicated conditions. Statistically significant differences (Student’s t-test) are
indicated. (d) Primary keratinocytes were transfected with the indicated siRNAs. The next day, cells were preincubated with zVAD-fmk (40 μM) alone or in combination with
necrostatin-1 (90 μM) for 60 min. Cells were then stimulated with TRAIL (100 ng/ml) overnight and viability was measured by crystal violet staining. Experiments revealed similar
results in keratinocytes from three different donors
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Figure 5 TRAIL-induced necroptosis is mediated by RIP3. HeLa cells stably infected with empty vector (VE) or a RIP3 expression plasmid were transiently transfected with
TRAF2 siRNA or control siRNA (a). After overnight incubation with Killer-TRAIL in triplicates of the indicated concentrations, cell viability was determined by crystal violet staining.
(b) The differently transfected HeLa cells were preincubated as indicated with zVAD-fmk (40 μM) and necrostatin-1 (90 μM) for 1 h and then challenged with Killer-TRAIL
(64 ng/ml). Cellular viability data after overnight incubation are shown from one out of three independent experiments). (c) Cells were stimulated with Killer-TRAIL in the presence
of the indicated mixtures of zVAD-fmk and necrostatin-1 for 3 h. Lysates were subjected to Western blot analysis (one out of two representative experiments is shown)
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Figure 6 Soluble TWEAK or BV6 induce depletion of cytoplasmic TRAF2/cIAP complexes and sensitise for TRAIL-induced necroptosis. HaCaT cells were preincubated
overnight with TWEAK (200 ng/ml) or medium as control (a, b) or with BV6 (10 μg/ml) or diluent (c, d). The next day, cells were preincubated with zVAD-fmk (40 μM) for 30 min as
indicated (b, d) and stimulated with TRAIL at various concentrations for 20 h (a–d). Viability was measured by crystal violet assay as described in Materials and Methods. One
representative out of four independent experiments is shown. (e) Cells were stimulated with TWEAK (200 ng/ml) overnight and thereafter either Triton X-100 lysates or whole cell
lysates were made. Lysates were analysed for the presence of the indicated proteins by Western blotting. (f–i) Empty vector control (VE) and ectopic RIP3 expressing HeLa cells
were treated as HaCaT cells in Figures 6b–d. One out of three experiments is shown
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We and others showed that stimulation of TRAF2-interacting
receptors such as TNFR2 and fibroblast growth factor-
inducible 14 (Fn14) lead to recruitment of TRAF2 and
TRAF2-containing complexes from the cytoplasm to a Triton
X-100 insoluble compartment,33–35 resulting in depletion of
the cytoplasmic pool of TRAF2 and limitation of the
availability of TRAF2 and TRAF2/cIAP complexes for other
receptors. In the context of TNFR1 signalling, priming of cells
with the Fn14 ligand TNF-like weak inducer of apoptosis
(TWEAK) leads to a strong enhancement of TNF-induced
caspase-8 activation and apoptosis.33,34 We thus analysed
the effects of Fn14 stimulation with soluble TWEAK on
TRAIL-induced cell death. In another setting we depleted
intracellular cIAPs by incubating the cells with the IAP
antagonist BV6.18 As has already been observed
previously,33 priming with TWEAK exerted no or at best a
minor sensitising effect on TRAIL-induced cell death in
HaCaT cells in the absence of caspase-8 inhibitory means
(Figure 6a). Of note, depletion of the Triton X-100 soluble
pool of TRAF2 and, accordingly, stabilisation of NFκB-
inducing kinase (NIK) and processing of NFκB p100 was
efficient in these cells (Figure 6e). In the presence of zVAD-
fmk, however, thus under necroptotic conditions, TWEAK
priming resulted in a significant sensitisation for both TRAIL-
and TNF-induced cell death (Figure 6b and Supplementary
Figure S3). Principally similar results were obtained in cells
that had been treated with the cIAP antagonist BV6 (Figures
6c and d). The necroptotic TRAIL–TWEAK crosstalk was
also evident in the RIP3 expressing HeLa transfectants, but
not in the parental HeLa cells lacking RIP3 expression
(Figures 6f and g and Supplementary Figure S5). Again
treatment with the cIAP antagonist BV6 showed similar
effects as TWEAK priming (Figures 6h and i). In summary,
these data show that TWEAK priming and BV6 treatment
specifically sensitise for TRAIL-induced necroptosis and in
this respect mimic a major effect observed with TRAF2 KD.
Thus, the latter may act partly by reducing the capacity of
cIAP1/2 to target RIP1.
Sensitisation towards TRAIL-induced necroptosis in
TRAF2 KD cells constitutes a genuine TRAIL signalling
effect and is not an indirect effect of TNF. Interference
with the activity of the TRAF2/cIAP complex, for example, by
use of second mitochondria-derived activator of caspases
(SMAC) mimetics, as well as stimulation with soluble TWEAK
can trigger in a cell-type dependent manner the induction of
endogenous TNF and subsequent TNFR activation.34,36
To exclude that cytoplasmic downregulation of TRAF2 either
by siRNA KD or by Fn14 signalling leads to sensitisation for
necroptosis via upregulation of endogenous TNFα and
TNFR-signalling, we performed TRAIL stimulation experi-
ments in the presence of TNFR2-Fc (Etanercept, Enbrel),
which inhibits TNFα and lymphotoxin α, or the antagonistic
anti-TNFα-antibody Adalimumab (Humira) (Figure 7;
Supplementary Figures S6 and S7). SK-OV3 cells, which
are known to exert an apoptotic TWEAK response via an
autocrine TNF loop served as a positive control to confirm
that the TNF blockers used were effective (Supplementary
Figure S2b). Effects of TRAIL or CD95L stimulation under
necroptotic conditions were not altered by co-incubation
with TNFR2-Fc or anti-TNFα, respectively (Figure 7,
Supplementary Figures S2a, S6 and S7). Inhibition of
classical NFκB signalling, which has a major role in TNF
induction but also induces survival proteins, with the IκB
kinase 2 (IKK2) inhibitor TPCA-1 did also not affect the
cell death-enhancing effects of TRAF2 KD (Supplementary
Figure S4). We thus conclude that the cell death-sensitizing
properties of TRAF2 KD observed in TRAIL-stimulated cells
reflect a genuine effect of TRAIL-related death signalling and
not an indirect TNF effect.
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Figure 7 TWEAK sensitises for TRAIL-induced necroptosis independent from endogenous TNF. HaCaT cells were seeded in 96-well plates and pretreated with TWEAK
(200 ng/ml) or medium control overnight. Cells were then pretreated for 1 h with zVAD-fmk (40 μM), necrostatin-1 (90 μM) or a combination of both and then stimulated with
TRAIL (64 ng/ml) in the presence or absence of TNFR2-Fc (Enbrel) (10 μg/ml). Viability was measured by crystal violet assay
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Discussion
TRAF2 is an adaptor protein that recruits cIAPs to TNFR1 and
to most non-DRs of the TNF receptor family.26 TRAF2 is
important for activation of the classical NFκB pathway by these
receptors but also mediates their stimulatory effects on the
c-Jun N-terminal kinase pathway.26 TRAF2 is also involved in
the constitutive cytosolic degradation of NIK, a MAP3K that
triggers the noncanonical NFκB signalling pathway.37 Most
TRAF2-interacting receptors can interfere with TRAF2-
dependent stimulation of NIK degradation by sequestration
of TRAF2 and therefore also activate the alternative NFκB
pathway;38,39 (Figure 6e). In the context of TNFR1 signalling,
TRAF2 along with TRAF1, cIAP1 and cIAP2 furthermore
antagonises caspase-8 activation and inhibits apoptosis
induction.40 Sequestration of TRAF2 and TRAF2-containing
complexes by TRAF2-interacting receptors therefore also
results in sensitisation for TNF-induced apoptosis.33,34,41–45
In this study, we evaluated the relevance of TRAF2 for
TRAIL- and CD95L-induced cell death. TRAF2 KD indeed
lowered the LC50 of TRAIL or CD95L for more than an order of
magnitude in HaCaTand HeLa cells (Figures 1a, 3a and 5a).
Noteworthy, TRAF2 KD not only reduced the LC50 of cell
death induction by TRAIL and CD95L but also partly changed
the quality of cell death. While control siRNA transfected
HaCaT cells were fully rescued from TRAIL- and CD95L-
induced cell death by the caspase inhibitor zVAD-fmk, TRAF2-
depleted HaCaT were only partly protected and required
a mixture of zVAD-fmk and the necroptosis inhibitor
necrostatin-1 for survival (Figures 2b, d and 3d). HeLa cells
treated with control siRNA and TRAF2 siRNA were in both
cases fully protected from TRAIL-induced cell death
(Figure 5b). HeLa cells, however, lack RIP3 expression and
are therefore completely refractory to DR-induced necropto-
sis. We therefore also analysed RIP3-transfected HeLa cells
with respect to the relevance of TRAF2 in TRAIL-induced cell
death. In this necroptosis-competent HeLa variant, we
observed roughly similar effects of TRAF2 KD on TRAIL-
induced cell death as in the endogenously RIP3 expressing
HaCaT cells, namely enhanced TRAIL-induced necroptosis in
the presence of zVAD-fmk (Figure 5b). In sum, these data
indicate that TRAF2 antagonises both DR-induced apoptosis
but especially DR-stimulated necroptosis.
Initially, the survival-promoting activities of TRAF2 have
mainly been investigated in the context of TNFR1 signalling
and have been assigned to the ability of TRAF2 to mediate
classical NFκB signalling, resulting in upregulation of NFκB-
controlled anti-apoptotic and anti-necrotic proteins, including
FLIP, ferritin heavy chain and manganese superoxide
dismutase.46–48 However, there is increasing evidence that
TRAF2 in concert with cIAP1 and cIAP2 also antagonises
TNFR1-induced cell death by an NFκB-independent mechan-
ism. For example, TRAF2 depletion by simultaneous or
delayed stimulation of TNFR2, in contrast to TNFR2 priming,
does not inhibit TNFR1-induced NFκB activation but still
significantly enhances TNFR1-induced apoptosis.44 Indeed,
the TRAF2-associated cIAPs have been found to inhibit TNF-
induced RIP1-mediated activation of caspase-8 by K63
ubiquitination of RIP1.49 Moreover, TRAF2 has recently been
identified as a K48 ubiquitin ligase for the p18 subunit of
matured heterotetrameric cytosolic caspase-8.27 The reduc-
tion of the latter activity in TRAF2 KD cells could contribute to
the sensitisation for TRAIL- and CD95L-induced caspase-
dependent apoptosis observed in these cells. This cIAP1/2-
independent function may also explain at least in part why
TWEAK, which depletes the cytosolic pool of TRAF2-cIAP1/2
complexes, and BV6, which induces degradation of cIAP1 and
cIAP2, in contrast to TRAF2 KD largely fail to enhance TRAIL-
induced apoptosis although both treatments similar to the
TRAF2 KD efficiently enhanced TRAIL-induced necroptosis
(Figure 6). TRAF2 has been furthermore implicated in TRAIL-
induced activation of the classical NFκB pathway.22,50,51
In fact, reduced basal and/or TRAIL/CD95L-inducible expres-
sion of anti-apoptotic and anti-necrotic proteins in TRAF2 KD
cells could explain both the enhancement of TRAIL/CD95L-
induced apoptosis and of TRAIL/CD95L-induced necroptosis.
TRAF2 KD, however, also sensitised cells in the presence of
cycloheximide, an inhibitor of protein synthesis, and in the
presence of the IKK2-inhibitor TPCA-1 (Supplementary Figure
S4), suggesting that the pro-survival activity of TRAF2 in
TRAIL- and CD95L-induced signalling is not dependent on
gene induction and protein synthesis. RIP1 can promote DR-
induced apoptosis but is also crucially involved in DR-induced
necroptosis. As on one side, necroptotic activity of RIP1 is
antagonised by cIAP1- and cIAP2-mediated ubiquitination12
and as on the other side cIAP1 and cIAP2 are recruited to
RIP1 via TRAF2, it appears plausible that the RIP1–caspase-
8 complex is the main target of the pro-survival activity of
TRAF2 in context of TRAIL- and CD95L-induced cell death.
Thus, the sensitising effect of TRAF2 KD on TRAIL-induced
necroptosis in caspase inhibited cells is possibly caused by
reduced recruitment of cIAPs to RIP1.
In view of the fact that TRAF2-interacting receptors inhibit by
sequestration cytosolic TRAF2–cIAP1/2 complex-related
activities, such as inhibition of the alternative NFκB pathway
and inhibition of TNF-induced caspase-8 activation,40–45 we
evaluated the effect of Fn14 stimulation on TRAIL-induced cell
death. Fn14 is a broadly expressed TRAF2-interacting
receptor of the TNF receptor family that, after stimulation by
its ligand TWEAK, strongly triggers the alternative NFκB
pathway.52,53 Moreover, priming cells for a few hours with
TWEAK results in depletion of the Triton X-100 soluble
cytosolic pool of TRAF2-cIAP1/2 complexes and reduced
TNF-induced TNFR1-associated ubiquitination of RIP1,
which, as mentioned before, is mediated by the cIAPs.33
TWEAK priming thus leads to attenuated activation of the
classical NFκB pathway and under appropriate conditions to a
tremendous sensitisation for TNF-induced cell death (200–
1000-fold).33 In the previous cited study no major effect of
TWEAK priming on TRAIL-induced apoptosis has been
found.33 However, the effect of TWEAK on TRAIL-induced
cell death had been investigated in the absence of caspase-8
inhibition and thus under conditions where DR-induced
necroptosis was blocked by caspase-8.12 As in our current
study the cell death sensitising effect of the TRAF2 KD was
most prominent in the context of TRAIL- and CD95L-induced
necroptosis, we looked for a possible TRAIL–TWEAK cross-
talk under necroptotic conditions (caspase-8 inhibition and
RIP3 expression). Indeed, under such conditions, we
observed a significant enhancement of TRAIL-induced cell
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death by TWEAK and by preincubation with the SMAC
mimetic BV6 (Figure 6). The fact that TWEAK sensitises cells
for apoptosis and necroptosis in the context of TNF signalling
but only for necroptosis in the context of TRAIL signalling
might reflect the differential relevance of the cytosolic RIP1–
caspase-8 complex for TNF- and TRAIL-induced apoptosis. In
TRAIL-induced apoptosis caspase-8 is primarily activated in
the receptor-associated signalling complex in a RIP1-
independent manner. In the context of TNFR1-induced
apoptosis, however, caspase-8 activation mainly takes place
in the secondarily formed cytosolic RIP1–caspase-8 complex.
This may also explain why BV6 primarily enhances TRAIL-
induced necroptosis. An ability of TRAIL to induce necroptosis
has often been suggested so far but only a very limited number
of studies have really shown necroptosis induction by
TRAIL.14,16 Our data confirm these observations and addi-
tionally prove in the experiments with TNFR2-Fc and with anti-
TNFα-antibody (Figure 7,Supplementary Figures S2) that the
TRAIL effect is not mediated via an autocrine TNF loop but is a
direct effect of TRAIL. Most importantly, however, by showing
that TRAF2 KD, TWEAK priming and BV6 treatment result in
enhanced TRAIL-induced necroptosis in the presence of a
caspase inhibitor, we give several lines of independent
evidence for an inhibitory role of TRAF2/cIAP complexes in
TRAIL- and CD95L-induced necroptotic signalling.
Materials and Methods
Materials. Antibodies with the following specificities were used for Western blot
analysis: TRAF2, β-actin (abcam, Cambridge, UK), Caspase-3, cIAP1, cIAP2 (Cell
signaling, Danvers, MA, USA), Caspase-8 (Enzo Life Sciences, Lausen, Switzer-
land), PARP, Cul3 (BD Pharmingen, Heidelberg, Germany), α-Tubulin (Millipore,
Billerica, MA, USA) and RIP3 (Imgenex, San Diego, CA, USA). HRP-conjugated
goat anti-mouse IgG1, goat anti-mouse IgG2a, goat anti-mouse IgG2b and
donkey anti-rabbit antibodies were obtained from Southern Biotech (Birmingham,
AL, USA) and Dianova (Hamburg, Germany). Killer-TRAIL was purchased from
Alexis biosciences (Carlsbad, CA, USA). The pan-caspase-inhibitor zVAD-fmk was
obtained from Bachem (Heidelberg, Germany). Necrostatin-1 was purchased from
Enzo Life Sciences (Lausen, Switzerland). Fc-CD95L and Flag-TWEAK were
produced as previously described.33 TRAF2 siRNA (HS-TRAF2_4, sequence
as follows: 5′-GGACCAAGACAAGAUUGAATT-3′), alternate TRAF2 siRNA’s
(HS-TRAF2_5, sequence: 5′-CGAGGGCAUAUAUGAAGAATT-3′; HS TRAF2_6,
sequence: 5′-GUUCGGCCUUCCCAGAUAATT-3′; HS TRAF2_7, sequence: 5′-GC
UGCGGAGCAGACGUGAATT-3′) and negative control siRNA were provided by
Qiagen (Hilden, Germany). siRNA transfection was performed with Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA).
Cell culture. The spontaneously transformed keratinocyte line HaCaT was
provided by P. Boukamp and cultured as previously described31 in Dulbecco’s
modified Eagle’s medium supplemented with 10% foetal calf serum at 37 °C with
5% CO2. Primary keratinocytes were separated from neonatal foreskin as
previously described,6 cultured in KGM (Promocell, Heidelberg, Germany) and used
between passages 2–5. HeLa cells transfected with empty vector and HeLa stably
transfected with RIP3 were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% foetal calf serum at 37 °C with 5% CO2. SK-OV3 cells were
cultured in RPMI supplemented with 10% foetal calf serum at 37 °C with 5% CO2.
siRNA transfection. For transient transfection, cells were incubated with
Lipofectamine 2000 and siRNA according to the Lipofectamine transfection protocol.
Briefly, 1 × 10 × 6 cells were seeded in a 10 cm culture dish. On the following day,
Lipofectamine (30 μl) and siRNA (20 μM) were equilibrated in Opti-MEM (3 ml) and
slowly added to the cells. Experiments were performed at day 1–5 post transfection.
KD efficiency was confirmed by Western blot analysis and typically found between
60 and 90%. All of the experiments were performed with TRAF2_4 siRNA from
Qiagen, but we could reproduce our results with other functional siRNAs for TRAF2
(Supplementary Figure S8).
Flow cytometry. Externalisation of phosphatidylserine to the outer membrane
was measured with the PE Annexin V Apoptosis Detection Kit (BD BioSciences
Pharmingen, Heidelberg, Germany) according to the manufacturer’s protocol.
Briefly, cells were seeded into six-well plates at a density of 1 × 10 × 5/well 1 day
prior to experiments. On the day of the experiment, the medium was changed and
cells were stimulated with Killer-TRAIL or Fc-CD95L for the indicated times (see
results). Cells were then detached, washed with ice-cold PBS and resuspended in
100 μl 1 × binding buffer. As a positive control for necrosis, cells were exposed to
heat-shock (55 °C for 30 min).54 Next, 5 μl Annexin V and 5 μl 7-AAD were added to
each sample and cells were incubated for 15 min in the dark. Cells were measured
on a FACSCanto flow cytometer (BD BioSciences, Heidelberg, Germany) and data
was analysed using the FACS DIVA software (BD BioSciences).
Western blot analysis. To prepare total cell lysates, cells were harvested,
washed with PBS and directly lysed in SDS sample buffer (2% SDS, 10% glycerol,
10% β-mercaptoethanol, 6% 1 M TRIS pH 6.8, dH2O, bromophenol blue).
To analyse the Triton X-100 soluble protein fraction, cells were lysed in Triton X-100
lysis buffer (1% Triton X-100, 10% glycerol, 3% 1 M TRIS pH 7.4, 6% 2 M NaCl,
dH2O) for 30 min on ice. Thereafter, the lysates were cleared by centrifugation for
15 min at 13 000 × g, mixed with SDS sample buffer and boiled at 95 °C for 5 min.
Lysates were separated by SDS-polyacrylamide gel electrophoresis in NuPage
4–12% Bis-Tris gels from Life technologies and transferred to nitrocellulose
membranes (Amersham, GE Healthcare, Freiburg, Germany). After blocking
nonspecific binding sites by incubation in Tris- or phosphate-buffered saline
containing 0.1% Tween 20 and 8% dry milk, Western blot analyses were carried out
with primary antibodies of the specificity of interest and horseradish peroxidase-
conjugated secondary antibodies (Southern Biotech) using ECL Western blotting
detection reagents (Pierce Thermo Scientific, Schwerte, Germany).
Cytotoxicity assay. 10 × 4 cells per well were seeded in 96-well plates and,
after adherence, were preincubated with Flag-TWEAK overnight in the TWEAK
experiments or with BV6 overnight in the BV6 experiments. The next day, cells were
stimulated with the indicated doses of Fc-CD95L or Killer-TRAIL in triplicates with or
without preincubation with zVAD-fmk and/or necrostatin-1. Cell viability was
determined by crystal violet staining after 16–20 h.
Data for figures. If not marked separately in the figure legends, the depicted
figures show one representative experiment of at least three independent
experiments performed.
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